---
title: "HERALD HOLD spent 81.5 million yuan to acquire a unit and parking space in Emperor Garden"
description: "HERALD HOLD announced that its indirectly wholly-owned subsidiary, HERALD PROPERTY, purchased Unit B, 18th Floor, Block 2, The Peak Galleria, 23 Old Peak Road, Hong Kong, along with Parking Space No. "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263471835.md"
published_at: "2025-10-30T09:06:08.000Z"
---

# HERALD HOLD spent 81.5 million yuan to acquire a unit and parking space in Emperor Garden

> HERALD HOLD announced that its indirectly wholly-owned subsidiary, HERALD PROPERTY, purchased Unit B, 18th Floor, Block 2, The Peak Galleria, 23 Old Peak Road, Hong Kong, along with Parking Space No. 6 on LG4 level of The Peak Galleria, for a price of HKD 81.5 million

HERALD HOLD (00114.HK) announced that its indirectly wholly-owned subsidiary, HERALD PROPERTY, purchased Unit B, 18th Floor, Block 2, The Peak, 23 Old Peak Road, Hong Kong, along with Parking Space No. 6 on LG4, for a price of HKD 81.5 million

### Related Stocks

- [00114.HK - HERALD HOLD](https://longbridge.com/en/quote/00114.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 15:37 ETStartups Compete for Cash and Investor Interest During Ski Lift Pitch at Taos Ski Valley | During the annual Ski Lift Pitch at Taos Ski Valley, 10 startups presented their business ideas to investors while ridin | [Link](https://longbridge.com/en/news/276076925.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| Beijing Haizhi Technology Announces Final Offer Price | Beijing Haizhi Technology Group Co Ltd:FINAL OFFER PRICE HK$27.06 PER H SHARE UNDER GLOBAL OFFERING | [Link](https://longbridge.com/en/news/275780031.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/en/news/276056763.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.